[Experimental study of human recombinant insulin].
The experimental study of recombinant human insulin revealed its high specific activity. The kinetics of the hypoglycemic effect of various dosage forms of the insulin developed at the National Research Centre of Antibiotics and the dosage forms manufactured by Eli Lilly was similar. The pharmacological investigation of the dosage forms showed that they had no side effects on the vitally important organs and systems. It was concluded that the dosage forms of the gene engineered human insulin developed at the National Research Centre of Antibiotics did not differ by their characteristics from the analogous dosage forms manufactured in other countries.
Iarotskiĭ
S V
SV
Nikitin
A V
AV
Berezhinskaia
V V
VV
Egorenko
G G
GG
Dolgova
G V
GV
D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D004361:Drug Tolerance; D006168:Guinea Pigs; D006943:Hyperglycemia / Q000097:blood / Q000188:drug therapy*; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use*; D051379:Mice; D011817:Rabbits; D051381:Rats; D011995:Recombination, Genetic; D013045:Species Specificity
D001786:Blood Glucose; D007328:Insulin
Eksperimental'noe izuchenie rekombinantnogo insulina cheloveka.